Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155647 · ClinicalTrials.gov registry record · Phase 2
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
A Phase 2 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT02155647 is a Phase 2 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 204 participants.
The verdict
NCT02155647, a Phase 2 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).
Interventions
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2014-07-03 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02155647
The ClinicalTrials.gov registry entry for NCT02155647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avelumab is the first listed.
NCT02155647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02155647 about?
NCT02155647 is a clinical study titled "Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)". This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).
What is the current status of trial NCT02155647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2014-07-03. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT02155647?
The interventions under investigation include: Avelumab (DRUG).
Who is sponsoring clinical trial NCT02155647?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.